COMPOUND AND METHODS FOR TREATING LONG QT SYNDROME
Granted: February 5, 2015
Application Number:
20150038489
Described herein is a method of treating long QT syndrome by administration of an effective amount of a potent and selective late sodium ion channel blocker
PHARMACEUTICAL COMPOSITIONS OF RANOLAZINE AND DRONEDARONE
Granted: February 5, 2015
Application Number:
20150037410
The present disclosure relates to a solid composition comprising ranolazine and a spray-dried phosphoric acid salt of dronedarone in a bilayer tablet.
METHODS OF MYOCARDIAL PERFUSION IMAGING
Granted: January 22, 2015
Application Number:
20150023867
The present invention provides a method of myocardial perfusion imaging using reduced doses of (1-{9-[(4S,2R,3R,5R)3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide.
MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
Granted: January 8, 2015
Application Number:
20150011775
The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS
Granted: December 11, 2014
Application Number:
20140364602
Methods and intermediates useful for preparing a compound of formula I: and salts thereof.
METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS
Granted: November 20, 2014
Application Number:
20140343063
The invention includes methods, compositions, and kits useful for treating a viral infection by administering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with atazanavir or a pharmaceutically acceptable salt thereof, and optionally with a compound that inhibits cytochrome P-450, or a pharmaceutically acceptable salt thereof.
METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS
Granted: November 20, 2014
Application Number:
20140343062
The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof.
BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS
Granted: November 13, 2014
Application Number:
20140336190
This application relates to chemical compounds which may act as inhibitors of; or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2, R2b, R3, R4a, R4b, and R5 are described herein.
COMBINATION THERAPY FOR THE TREATMENT OF ARRHYTHMIAS OR HEART FAILURE
Granted: November 6, 2014
Application Number:
20140329755
The present invention relates to method of treating arrhythmias or heart failure comprising co-administration of a late INa inhibitor and a CAMK II inhibitor.
FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
Granted: October 9, 2014
Application Number:
20140303158
The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1, W2, W3, R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS
Granted: October 2, 2014
Application Number:
20140296246
This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2a, R2b, R3, and X are described herein.
INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
Granted: October 2, 2014
Application Number:
20140296228
Compounds of formula I: wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.
ANTIVIRAL COMPOUNDS
Granted: September 25, 2014
Application Number:
20140288294
The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
SYNTHESIS OF AN ANTIVIRAL COMPOUND
Granted: September 18, 2014
Application Number:
20140275570
The present disclosure provides processes for the preparation of a compound of Formula I: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula.
COMPOSITIONS AND METHODS OF TREATING PULMONARY HYPERTENSION
Granted: September 18, 2014
Application Number:
20140275098
Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations.
METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS
Granted: August 28, 2014
Application Number:
20140243358
The invention is related to methods of preventing and treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.
INHALABLE AZTREONAM LYSINATE FORMULATION FOR TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS
Granted: August 28, 2014
Application Number:
20140243304
A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a…
2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS
Granted: August 21, 2014
Application Number:
20140235563
Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2?,4?-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections.
APOPTOSIS SIGNAL-REGULATING KINASE INHIBITOR
Granted: August 14, 2014
Application Number:
20140228411
The present invention relates to a compound of formula (I): The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.
APOPTOSIS SIGNAL-REGULATING KINASE INHIBITOR
Granted: August 14, 2014
Application Number:
20140228412
The present invention relates to a compound of formula (I): The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.
